Diseases /
Cancer
Back to Diseases List
Associated Genetic Biomarkers
Overview
Cancers most frequently harbor alterations in TP53, KRAS, PIK3CA, APC, and CDKN2A [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in cancer [2].
Clinical Trials
There are 75 clinical trials for cancer, of which 40 are open and 35 are completed or closed. Of the trials that contain cancer as an inclusion criterion, 2 are early phase 1 (0 open), 33 are phase 1 (21 open), 15 are phase 1/phase 2 (9 open), 17 are phase 2 (6 open), and 8 are no phase specified (4 open).
HLA-A*02:01, CDKN2A, and CTAG1A are the most frequent gene inclusion criteria for cancer clinical trials [3].
Cyclophosphamide, fludarabine, and nivolumab are the most common interventions in cancer clinical trials.
Significant Genes in Cancer
APOBEC2 +
APOBEC2 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains APOBEC2 status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
APOBEC3A +
APOBEC3A is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3A status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
APOBEC3B +
APOBEC3B is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3B status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
APOBEC3C +
APOBEC3C is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3C status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
APOBEC3D +
APOBEC3D is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3D status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
APOBEC3F +
APOBEC3F is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3F status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
APOBEC3H +
APOBEC3H is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3H status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
APOBEC4 +
APOBEC4 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains APOBEC4 status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CCNE2 +
CCNE2 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains CCNE2 status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 5.14% of cancer patients [2].
ERBB2 is an inclusion eligibility criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 1 is phase 1/phase 2 (1 open) [3].
FGF1 +
FGF1 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF1 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [3].
FGF11 +
FGF11 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF11 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [3].
FGF13 +
FGF13 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF13 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [3].
FGF17 +
FGF17 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF17 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF2 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [3].
FGF20 +
FGF20 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF20 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [3].
FGF22 +
FGF22 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF22 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [3].
FGF9 +
FGF9 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF9 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [3].
MAGEA3 +
MAGEA3 is an inclusion eligibility criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains MAGEA3 status and cancer as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MTOR +
MTOR is altered in 3.46% of cancer patients [2].
MTOR is an inclusion eligibility criterion in 3 clinical trials for cancer, of which 1 is open and 2 are closed. Of the trials that contain MTOR status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 1 is phase 2 (0 open) [3].
PDGFRA +
PDGFRA is altered in 2.87% of cancer patients [2].
PDGFRA is an inclusion eligibility criterion in 4 clinical trials for cancer, of which 2 are open and 2 are closed. Of the trials that contain PDGFRA status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 2 are phase 2 (1 open) [3].
PIK3CA +
PIK3CA is altered in 13.11% of cancer patients [2].
PIK3CA is an inclusion eligibility criterion in 3 clinical trials for cancer, of which 1 is open and 2 are closed. Of the trials that contain PIK3CA status and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 2 are phase 1 (1 open) [3].
TSC1 +
TSC1 is altered in 2.22% of cancer patients [2].
TSC1 is an inclusion eligibility criterion in 3 clinical trials for cancer, of which 1 is open and 2 are closed. Of the trials that contain TSC1 status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 1 is phase 2 (0 open) [3].
TSC2 +
TSC2 is altered in 3.44% of cancer patients [2].
TSC2 is an inclusion eligibility criterion in 3 clinical trials for cancer, of which 1 is open and 2 are closed. Of the trials that contain TSC2 status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 1 is phase 2 (0 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.